With all the consolidation that’s taking place, practices are still trying to grow, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
With all the consolidation that’s taking place, practices are still trying to grow, explained Terrill Jordan, chief executive officer of Regional Cancer Care Associates.
With a high prevalence of hospital consolidation, do practices have challenges with trying to grow and diversify?
With all the consolidation that’s taking place, practices are still trying to grow. I think they face the same things they’ve always faced. I don’t know that consolidation necessarily limited their ability to grow—I think in fact some of the consolidation that takes place is amongst larger practices. So, in fact, it’s probably allowed for more growth. I think in terms of a smaller practice trying to grow, I think what they need to look to is the same things they’ve always looked to. In fact, what we’re seeing is that some hospitals are having practices leave the hospital and so there’s some growth there.
I think the demographics of the country also just naturally support growth. So, we’re going to see larger growth simply because more persons are going on Medicare, the population is aging, and so forth.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More